Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Renal clearable CRISPR nanosensor targeting mitochondrial DNA mutation for noninvasive monitoring of tumor progression and metastasis.

Science advances - 21 Nov 2025

Li Yanan, Wu Yonghua, Zheng Ziyue, Wu Yige, Zhang Yongyuan, Zhang Jingjing, Quan Fenglei, Zhao Wen, Xu Ru, Li Yiwei, Gao Hua, Zhang Kaixiang

Abstract excerpt

Mitochondrial DNA (mtDNA) mutations are emerging as important molecular features of tumorigenesis. Liquid biopsies, involving analysis of cell-free mtDNA, enable early cancer detection but suffer from low sensitivity due to scarce analytes. Here, we developed a CRISPR/Cas12a-mediated urinary biomarker, termed CasUber, for in vivo monitoring of tumor progression and metastasis. Our results demonstrate that CasUber...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biosensing Techniques
Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell-Free Nucleic Acids

Share to CRISPR-Cas Systems

Share to Liquid Biopsy

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to Neoplasms, Experimental

Source

Open in PubMed Open full text

Identifiers

PMID: 41270157
DOI: 10.1126/sciadv.adz4594
PMCID: PMC12637282

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Renal clearable CRISPR nanosensor targeting mitochondrial DNA mutation for noninvasive monitoring of tumor progression and metastasis.PMID 41270157Read ↗

CRISPR-Cas-amplified urine biomarkers for multiplexed and portable cancer diagnosticsSemantic proximity Read ↗

CRISPR-Cas-amplified urine biomarkers for multiplexed and portable cancer diagnosticsSemantic proximity Read ↗

In vivo imaging of mitochondrial DNA mutations using an integrated nano Cas12a sensor.Semantic proximity Read ↗

Single-nucleotide variant profiling in liquid biopsy with RECO-Cas.Semantic proximity Read ↗

Near-Infrared Light-Inducible CRISPR-Cas12a/Tetrahedral DNA Nanosystem for Spatiotemporal Control of mtDNA Mutation Imaging and Gene Therapy.Semantic proximity Read ↗

A CRISPR Test for Rapidly and Sensitively Detecting Circulating EGFR MutationsSemantic proximity Read ↗

CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma.Semantic proximity Read ↗

Allele-Specific CRISPR-Cas9-Based Ratiometric Fluorescence Platform for Portable EGFR L858R Mutation Detection.Semantic proximity Read ↗

In Situ Amplified Mutational mRNA Imaging Using a Spatially Confined CRISPR Nanoplatform.Semantic proximity Read ↗

Genotype-specific precision tumor therapy using mitochondrial DNA mutation-induced drug release system.Semantic proximity Read ↗

TtAgo-coupled-multiplex-digtal-RPA-CRISPR/Cas12a (TCMDC) for EGFR mutations detection.Semantic proximity Read ↗

Non-Invasive Urine-Based Diagnostic Technologies for Early Bladder CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.